AcuFocus Inc. raised $65 million in investments and equity financing in support of its Kamra corneal inlay treatment for near vision loss, or presbyopia.
The Kamra device is already on the market in areas in Europe, Asia-Pacific, the Middle East and South America, according to a press release.
It has CE Mark approval in the European Union and is under an investigational device exemption in the U.S.